Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-20

Study Completion Date

2015-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU). The study will compare number and types of adverse events occured, rates of wound closure and percentage of wounds closed in Galnobax treated groups versus placebo group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT04435665

Neurofibromatosis 1 Cutaneous Neurofibroma

COMPLETED PHASE2

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

NCT02338336

Plantar Warts

COMPLETED PHASE1/PHASE2

Clinical Trial of Anusol Ointment for Symptom Relief in Patients With Haemorrhoids

NCT05157711

Hemorrhoids

COMPLETED PHASE3

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

NCT02239731

Rash Due to Epidermal Growth Factor Receptor Inhibitors

COMPLETED PHASE2

A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia

NCT00154089

Cervical Intraepithelial Neoplasia

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an interventional, placebo-controlled, randomized, double-blinded, dose comparison, phase I/II study of Galnobax® in subjects with diabetic foot ulcers. Additionally the effect of dosage and frequency of application will also be studied . The total trial duration per subject is 25 weeks which comprises of 1 week for screening, 12 weeks of treatment and 12 weeks of follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo gel

Group Type PLACEBO_COMPARATOR

Placebo gel

Intervention Type DRUG

Galnobax 20% QD

Esmolol Hydrochloride (Galnobax) 20% gel once daily

Group Type EXPERIMENTAL

Esmolol hydrochloride

Intervention Type DRUG

Galnobax 20% BID

Esmolol Hydrochloride (Galnobax) 20% gel twice daily

Group Type EXPERIMENTAL

Esmolol hydrochloride

Intervention Type DRUG

Galnobax 14% BID

Esmolol Hydrochloride (Galnobax) 14% gel twice daily

Group Type EXPERIMENTAL

Esmolol hydrochloride

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esmolol hydrochloride

Intervention Type DRUG

Esmolol hydrochloride

Intervention Type DRUG

Esmolol hydrochloride

Intervention Type DRUG

Placebo gel

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Galnobax-14% Galnobax-20% Galnobax-QD Placebo control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects aged 18 to 95 years, inclusive, with Type 1 or Type 2 diabetes undergoing therapy for glycemic control
* Subjects having below knee ulcer of at least 4 week and maximum of 52 weeks duration which is a full thickness ulcer without exposure of bone, muscle, ligaments, or tendons
* Ulcer should be clinically non-infected
* Ulcer area (length x width) measurement between 1.5 cm2 and 10 cm2, inclusive and post debridement ulcer area less than or equal to 12 cm2.
* Full-thickness ulcer of Grade 1 or Grade 2 as per Wagner's classification system
* Recently debrided ulcer (2 weeks prior to screening) and post debridement ulcer free of necrotic debris, foreign bodies, sinus tracts, tunneling, and undermining, comprised of healthy vascularized tissue as determined by the Investigator
* Inability to perceive 10 grams pressure using Semmes-Weinstein 5.07 monofilament in the peri-ulcer area
* Ankle Brachial index between 0.7 and 1.2

Exclusion Criteria

* Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis.
* Subjects having cellulitis, ischemic or gangrenous ulcers in the opinion of the Investigator
* Glycosylated hemoglobin (HbA1C) \>12%
* Diagnosed and/ currently unstable hypotension, heart block, cardiac failure, and other cardiac complications
* Subject diagnosed with cancer undergoing chemotherapy
* Revascularization surgery 4 weeks prior to signing the ICF
* Renal failure as defined by serum creatinine \>3.0 mg/dL or renal insufficiency requiring frequent dialysis
* Poor nutritional status as measured by serum albumin \<3.0 g/dL
* Active Charcot or other structural deformity that would prevent adequate off-loading of the study foot

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No